Table 3.
Overall experience with administration of study medication.
| Patients’ experiences (N = 93) | HCP perspectives of patients’ experiences (N = 42) | HCP own experiences (N = 42) | |
|---|---|---|---|
| Improvement in UC outweighed any dissatisfaction with the administration of mirikizumab, n (%) | |||
| Strongly agree | 67 (72) | 20 (48) | 26 (62) |
| Agree | 17 (18) | 17 (41) | 14 (33) |
| Neither agree nor disagree | 4 (4) | 5 (12) | 1 (2) |
| Disagree | 4 (4) | 0 (0) | 1 (2) |
| Strongly disagree | 1 (1) | 0 (0) | 0 (0) |
| Overall satisfaction with mirikizumab, n (%) | |||
| Very satisfied | 71 (76) | 27 (64) | 28 (67) |
| Satisfied | 20 (22) | 13 (31) | 13 (31) |
| Neither satisfied nor unsatisfied | 2 (2) | 1 (2) | 1 (2.4) |
| Unsatisfied | 0 (0) | 1 (2) | 0 (0) |
| Very unsatisfied | 0 (0) | 0 (0) | 0 (0) |
| Overall acceptability of administration of mirikizumab, n (%) | |||
| Completely acceptable | 88 (95) | 39 (93) | NA |
| Somewhat acceptable | 3 (3) | 2 (5) | NA |
| Neither acceptable nor unacceptable | 1 (1) | 1 (2) | NA |
| Somewhat unacceptable | 1 (1) | 0 (0) | NA |
| Completely unacceptable | 0 (0) | 0 (0) | NA |
| Recommend mirikizumab to someone with UC, n (%) | |||
| Strongly agree | 69 (74) | 28 (67) | NA |
| Agree | 21 (23) | 13 (31) | NA |
| Neither agree nor disagree | 2 (2) | 1 (2) | NA |
| Disagree | 1 (1) | 0 (0) | NA |
| Strongly disagree | 0 (0) | 0 (0) | NA |
| Found SC self-injection device easy to use, n (%) | |||
| Strongly agree | 25 (61) | 23 (55) | 32 (76) |
| Agree | 14 (34) | 9 (21) | 5 (12) |
| Neither agree nor disagree | 1 (2) | 8 (19) | 3 (7) |
| Disagree | 1 (2) | 2 (5) | 2 (5) |
Abbreviations: HCP, healthcare provider; NA, not applicable; SC, subcutaneous; UC, ulcerative colitis.